Atherosclerosis in systemic lupus erythematosus

Area of Science:

• Rheumatology
• Immunology
• Cardiology

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease with significant cardiovascular morbidity and mortality.
• Atherosclerosis, a key contributor to cardiovascular events in SLE, shares inflammatory characteristics with autoimmune processes.
• Cardiovascular manifestations are a leading cause of late-stage mortality in SLE patients.

Purpose of the Study:

• To review the multifaceted risk factors contributing to accelerated atherosclerosis in SLE patients.
• To highlight the interplay between traditional, disease-related, and specific inflammatory mechanisms driving cardiovascular risk in SLE.
• To emphasize the need for targeted surveillance and prevention strategies for atherosclerosis in SLE.

Main Methods:

• Literature review and synthesis of existing research on SLE and cardiovascular disease.
• Analysis of traditional cardiovascular risk factors (e.g., Framingham risk factors) in the context of SLE.
• Examination of SLE-specific factors including disease duration, steroid use, renal involvement, and inflammatory markers.

Main Results:

• SLE patients exhibit increased risk for both atherosclerotic and thromboembolic cardiovascular events.
• Risk factors include traditional ones, disease duration, steroid therapy, renal disease, and specific autoimmune responses.
• Key inflammatory mechanisms involve antibodies to beta2GPI, anticardiolipin, oxidized LDL, heat shock proteins, complement activation, impaired TGF-beta1 activation, and elevated CRP.

Conclusions:

• Accelerated atherosclerosis is a major concern in SLE, driven by a combination of factors.
• Effective management requires addressing both traditional and SLE-specific risk factors.
• Proactive surveillance and preventive measures are crucial to mitigate cardiovascular events in SLE patients.